Depression

Review the uses and forms of transcranial magnetic stimulation.

From new guidelines for the utilization of artificial intelligence in health care to the efficacy of fish oil as a replacement for antidepressants, here are highlights from the week in Psychiatric Times.

Is finding meaning conducive to healing?

Could fish oil replace antidepressants as a first-line pill for depression?

Psychiatric treatment works to a degree comparable to other branches of medicine which address complex, chronic illnesses.

From a new look at the famous STAR*D study to updates from the National Academy of Sciences Conference on Adult ADHD, here are highlights from the week in Psychiatric Times.

Since 2006, STAR*D stands out as an icon guiding treatment decisions of major depressive disorder. But what if it is broken?

These important findings on esketamine nasal spray as a treatment for young individuals with suicidal ideation were presented at the ACNP 2023 Annual Meeting. We interviewed the vice president and head of neuropsychiatry clinical development at Johnson & Johnson Innovative Medicine to learn more.

From adjunctive cariprazine for the treatment of major depressive disorder to a new app for prescribing antidepressants and antipsychotics, here are highlights from the week in Psychiatric Times.

ECT: a gold-standard treatment for major depressive disorder. Ketamine/esketamine: a newer therapeutic option. This ACNP 2023 Annual Meeting session took a deeper look.

This ACNP 2023 Annual Meeting poster covered a 26-week study on cariprazine as an adjunctive treatment to antidepressants in patients with major depressive disorder.

Neurosteroid therapeutics could be the solution to provide fast-acting treatment for mothers with postpartum depression.

DBS in psychiatry: What challenges stand between this treatment and success? Alik Widge, MD, PhD, shares more at the ACNP 2023 Annual meeting.

Did you catch the President's Plenary at the ACNP 2023 Annual Meeting?

Navacaprant—a novel, oral, once-daily, highly selective kappa opioid receptor antagonist that is currently in phase 3 development as a monotherapy for major depressive disorder.

From dopamine detoxification for problem gaming to connections between bacteria and anxiety and depression, here are highlights from the week in Psychiatric Times.

What is new in research on bipolar disorder?

How can we offer options and hope for the future to patients with treatment-resistant depression?

The results suggest that the bacterium Lactobacillus may aid in the management of stress and in the prevention of these disorders.

The experts weighed in on a wide variety of psychiatric issues for the November 2023 issue of Psychiatric Times.

Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.

Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.

From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

What is new in research on anxiety symptoms and disorders?